Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
Proc Natl Acad Sci U S A
; 120(24): e2216612120, 2023 06 13.
Article
in En
| MEDLINE
| ID: mdl-37276407
Full text:
1
Database:
MEDLINE
Main subject:
Single-Domain Antibodies
/
COVID-19
Limits:
Humans
Language:
En
Journal:
Proc Natl Acad Sci U S A
Year:
2023
Type:
Article